Trends in prostate cancer incidence

Trends in United States prostate cancer incidence rates by age and stage, 1995-2012

Richard M. Hoffman1,2
Angela L. W. Meisner3
Wadih Arap3,4
Marc Barry3,5
Satyan K. Shah6
Steven B. Zeliadt7
Charles L. Wiggins3,4

1Department of Medicine, University of Iowa Carver College of Medicine
2Holden Comprehensive Cancer Center, University of Iowa
3University of New Mexico Comprehensive Cancer Center
4Department of Internal Medicine, University of New Mexico
5Department of Pathology, University of New Mexico
6Department of Surgery, University of New Mexico
7Puget Sound VA Healthcare System

Running title: Trends in prostate cancer incidence

Key words: prostatic neoplasms, early detection of cancer, practice guideline, epidemiology, neoplasm staging
Funding

National Cancer Institute (NCI) contract number HHSN26120130010I, Task Order HHSN26100005, supports, in part, CL Wiggins and ALW Meisner. The National Cancer Institute and the University of New Mexico Comprehensive Cancer Center Support Grant through Grant Number 2P30CA118100-1 supports, in part, CL Wiggins, W Arap, M Barry, and S Shah.

Corresponding author:

Richard M. Hoffman, MD, MPH
200 Hawkins Drive
SE 618 GH
Iowa City, IA 52252
richard-m-hoffman@uiowa.edu
Tel: 319-384-8511
Fax: 319-356-3086

Conflicts of Interest

None of the authors have any conflicts of interest to declare.

Abstract word count: 212
Word count: 1915
Abstract

Background: The advent of PSA testing in the late 1980s substantially increased prostate cancer incidence rates. Concerns about overscreening and overdiagnosis subsequently led professional guidelines (circa 2000 and later) to recommend against routine PSA testing. We evaluated trends in prostate cancer incidence, including late-stage diagnoses, from 1995 through 2012.

Methods. We used joinpoint regression analyses to evaluate all-, localized/regional-, and distant-stage prostate cancer incidence trends based on Surveillance, Epidemiology, and End Results (SEER) data. We stratified analyses by age (50-69, 70+). We reported incidence trends as annual percent change (APC).

Results: Overall age-adjusted incidence rates for localized/regional stage PCa have been declining since 2001, sharply from 2010 to 2012 (APC -13.1, 95% CI -23.5 to -1.3).

Distant-stage incidence rates have declined since 1995, with greater declines from 1995 to 1997 (APC – 8.4, 95% CI -2.3 to -14.1) than from 2003 to 2012 (APC – 1.0, 95% CI –1.7 to -0.4). Distant-stage incidence rates declined for men 75+ from 1995 to 2012, but increased in men 50-69 from 2004 to 2012 (APC 1.7, 95% CI 0.2 to 3.2).

Conclusions: Guidelines discouraging routine prostate cancer screening were temporally associated with declining localized/regional prostate cancer incidence rates; however, incidence rates of distant-stage disease are now increasing in younger men.

Impact: This trend may adversely affect prostate cancer mortality rates.
Trends in prostate cancer incidence

Introduction

In the early 1990s, the American Urological Association (AUA) and the American Cancer Society (ACS) began recommending routine annual prostate cancer screening with prostate-specific antigen (PSA). (1, 2) Although these recommendations were not supported by clinical trial evidence, the resultant increase in screening led to a substantial rise in prostate cancer incidence. By 1992, the U.S. age-adjusted prostate cancer incidence rate reached 237.4 per 100,000, nearly double the rate in 1986 when PSA was first approved. (3) Incidence rates subsequently dropped, though remaining substantially higher than before the PSA era.

By 2000, given concerns about the potential harms of overdiagnosis and overtreatment, revised ACS (4) and AUA (5) guidelines were recommending against routine screening, advising providers instead to support informed decision making. In 2008, the U.S. Preventive Services Task Force (USPSTF) recommended against screening men older than age 75. (6) The major screening trials, European Randomized Study of Screening for Prostate Cancer (ERSPC) (7) and Prostate, Lung, Colorectal, and Ovarian Cancer Screening trial (PLCO), (8) first published cancer survival data in 2009. The ERSPC reported a modest prostate cancer survival benefit with screening, while the PLCO found no benefit. Subsequent guidelines issued by the ACS in 2010 (9) and the AUA in 2013 (10) again affirmed the importance of informed decision making. Meanwhile, in October 2011 the USPSTF issued a draft document recommending against any PSA-
Trends in prostate cancer incidence

based screening for prostate cancer,(11) a position endorsed by the final guideline published in July 2012.(12)

Numerous studies have evaluated the temporal associations of publishing screening guidelines and clinical trial results on screening practices and attitudes.(13-23)

However, most studies focused on the impact of the 2008 USPSTF guidelines. Moreover, we found only one study that comprehensively evaluated stage-specific cancer incidence trends, but data were available only through 2007.(24). Therefore, we used the most recent (April 23, 2015) National Cancer Institute’s (NCI) SEER program data to evaluate age- and stage-specific trends in prostate cancer incidence from 1995 through 2012.(3)

Materials and Methods

Our study was based on incident cases of prostate cancer diagnosed among residents of 13 geographic areas covered by the SEER program. We identified eligible cases by using International Classification of Diseases for Oncology (ICDO-3) topography code C61.9 (prostate) and ICDO-3 behavior code 3 (malignant). We excluded lymphomas (ICDO-3 morphology codes 9590-9989), Kaposi sarcomas (ICDO-3 morphology code 9140), and mesotheliomas (ICDO-3 morphology codes 9050-9055), along with benign and in situ prostate tumors. We calculated average annual age-adjusted incidence rates by the direct method and standardized them to the age distribution of the projected 2000 United States population. We also calculated average annual age-adjusted incidence
rates by stage. The SEER program classifies stage as localized/regional (defined as
equipped to the prostate/extraprostatic extension into surrounding tissue ± regional
lymph node involvement), and distant (defined as invasion to distant organs or distant
lymph nodes). We used the SEER Historic A staging to ensure comparability over time.
We excluded cancers of unknown stage from trend analyses. We further stratified
results by age group (50 to 69, 70 and older) because screening guidelines now
recommend offering screening only to men ages 50 to 69.(9, 10) We excluded men
younger than 50 because guidelines did not recommend routine screening for this age
group and sample sizes were too small to perform longitudinal analyses. We use the
NCI’s SEER*Stat software to calculate incidence rates.(25) We analyzed data from 1995
to 2012, the period covered by the SEER Historic A composite stage variable for prostate
cancer.

We used joinpoint analyses to assess temporal trends in annual age-adjusted and age-
specific incidence rates for all races combined for all-stage, localized/regional, and
distant-stage prostate cancers.(26, 27) The joinpoint software fits the simplest model to
describe the incidence rate trend data, starting with a straight line (0 joinpoints) and
then adding more joinpoints to determine whether multiple connecting lines better
describe the data points. The software identifies the year(s) when the APC trends
appear to shift upward or downward and whether these trends are statistically
significant. In describing trends, we use the terms increased or decreased only when the
slope (annual percent change [APC]) was statistically significant (2-sided P-value < 0.05).
Figure 1 shows joinpoint curves plotted on a logarithmic scale. We used this scale to better display incidence rates for both localized/regional and distant-stage cancer on the same graph because there is a nearly 2 order-of-magnitude difference between the stage-specific rates. The University of New Mexico Human Research Review Committee classified this study as exempt research.

Results

Age-adjusted localized/regional-stage prostate cancer incidence rates increased from 1995 to 2001; rates gradually declined from 2001 to 2010 before sharply declining from 2010 to 2012 (Table 1). The age-adjusted incidence trends for localized/regional cancers closely track with all-stage age-adjusted incidence trends. The incidence rate of distant-stage disease declined sharply from 1995 to 1997, and then declined more gradually from 1997 to 2012.

Among men ages 50 to 69, localized/regional stage incidence rates were stable from 1995 to 2010 before sharply declining from 2010 to 2012 (Figure 1). Localized/regional-stage incidence rates were stable from 1995 to 2000 for men 70 and older; rates declined from 2000 to 2012 with a steeper decline from 2007 to 2012 (Figure 1). The age-specific incidence trends for localized/regional cancers closely track with all-stage age-specific incidence trends (data not shown).
Trends in prostate cancer incidence

Among men ages 50 to 69, the incidence rate for distant-stage disease declined from 1995 to 2004, but increased from 2004 to 2012. Rates for distant-stage disease among men 70 and older declined from 1995 to 2012, though more gradually from 2001 to 2012.

Discussion

Using SEER population-based cancer data from 1995 through 2012, we found declining all-stage and localized/regional, age-adjusted incidence rates for prostate cancer since 2001 that were temporally associated with ACS and AUA recommendations against routine screening issued around 2000.(4, 5) Age-adjusted incidence rates of distant-stage prostate cancer have also declined since 1995, a time period when prostate cancer mortality rates were significantly declining across all age groups.(3) Age-specific all-stage incidence rates have been steadily decreasing among older men since 2000, a trend consistent with recommendations against screening men with limited life expectancy. Rates have declined only recently among younger men, which could reflect the October 2011 release of the draft USPSTF D rating against screening. (28)

Incidence rates of distant-stage prostate cancer were consistently higher for older than younger men. Further, the temporal patterns differed by age. Incidence rates declined throughout the study period for older men, though the rate of decline was less steep after 2001. Among young men, rates declined from 1995 to 2004, but then gradually increased from 2004-2012. Several factors could be affecting our observations.
Trends in prostate cancer incidence

Younger men tend to have more aggressive cancers so a decline in screening might more quickly impact them.\(^{(29)}\) Additionally, we may be seeing a lag-time effect where a cancer developing in a man in his late 60s that was not detected by screening could present clinically at a distant stage when the man was 70 and older. This suggests that the rate of distant-stage disease might not continue to decline in older men.

The initial recommendations for routine prostate cancer screening in the early 1990s by the AUA and ACS clearly influenced clinical practice because they were associated with a dramatic increase in the incidence of prostate cancer, particularly early-stage cancers.\(^{(1-3)}\) The 2000 National Health Interview Survey (NHIS) found that 57% of men aged 50 and older reported ever screening, including 34% within the past year.\(^{(30)}\) The 2001 Behavioral Risk Factor Surveillance System survey found even higher screening percentages; 75% of men aged 50 and older reported ever PSA testing, including 57% within the past year.\(^{(31)}\)

However, determining the effects of subsequent recommendations on screening practice is challenging. Most studies have focused on the 2008 USPSTF recommendation against screening men over age 75 and findings were inconsistent. NHIS data showed no change in screening among older men between the 2005 (43%) and 2010 (44%) surveys.\(^{(32)}\) Similarly, an analysis of the CDC’s Behavioral Risk Factor Surveillance System data showed no changes in PSA testing among older men, with rates of 60% in 2006, 63% in 2008, and 60% in 2010.\(^{(20)}\) A limitation of these data is
that screening is self-reported by participants. In contrast, screening data captured by the SEER Medicare files did show a significant, though small, decline between Spring 2008 (29.4%) and Fall 2009 (27.8%), with a slight increase in screening among men ages 66 to 74.\(^{(19)}\) Investigators using data from the Medicare Current Beneficiary Survey Access to Care estimated that the 2008 USPSTF recommendation was associated with a 5.3 percentage point decline in annual PSA testing rate among men aged 75 and older, from about 47% to 42%.\(^{(17)}\)

We found only one study that evaluated the national impact of the 2012 USPSTF recommendation on prostate cancer screening.\(^{(33)}\) Between 2010 and 2013, NHIS data showed significant declines in self-reported PSA screening for men ages 50 to 59 (33.2% to 24.8%), men ages 60 to 74 (51.2% to 43.6%), and men ages 75 and older (43.9% to 37.1%). Several practice-level studies also reported declines in PSA testing by the end of 2012.\(^{(13, 14)}\)

The impact of these screening trends on clinical outcomes is uncertain. One early signal that PSA screening might be effective was the decline in the incidence of distant stage cancer by 1995.\(^{(34)}\) Therefore, an early indicator that less screening—and resultant decrease in prostate cancer incidence—might be harmful would be an increase in the incidence rate of distant-stage disease. Howard and colleagues, using SEER data, did not observe such an increase immediately following the 2008 USPSTF guidelines; between 2007 to 2009, adjusted overall incidence rate for men 75+ significantly decreased by
Trends in prostate cancer incidence

25.4% while the adjusted incidence rate of late stage tumors decreased by 14.3%.(17)

In extending follow up through 2012, we found continued declines in the incidence of distant-stage disease among older men, though with a less negative slope. However, we also observed a gradually increasing incidence of distant-stage disease among men 50 to 69 years from 2004 to 2012.

Other studies have attempted to hone in on the short-term consequences of the USPSTF draft guidelines using more surrogate clinical endpoints. A single-center Canadian study showed a sharp decline in biopsy referrals and the absolute number of cancer diagnoses, including those with high-grade disease, beginning in May 2012.(28) Investigators attributed their findings to decreased screening in response to the USPSTF guideline. Another recent publication looking at incident prostate cancer cases in the National Cancer Data Base diagnosed from January 2010 through December 2012 found a 12.2% percent drop in incident cases in the month following the draft guideline and a 28% decline over the following year.(35) Significant declines were observed for localized cancer diagnoses, including those with high-risk features, though new diagnoses of non-localized cancers did not change.

Our study has some important limitations. More time is needed to tell whether our findings signify a major shift in prostate cancer incidence. Before adding the 2012 data, the estimated increase in APC for distant-stage disease in younger men was not statistically significant. We do not know the screening history of men diagnosed with
distant-stage prostate cancer so can note only an association between screening trends and incidence of distant-stage disease. However, with recent ACS and AUA guidelines both taking more cautious approaches to screening and the USPSTF advising against any screening, PSA testing might continue to decrease. Less screening will decrease the overall incidence of prostate cancer and reduce the risk of overdiagnosis. A concomitantly rising rate of distant disease among younger men could potentially increase prostate cancer mortality rates.
References


Trends in prostate cancer incidence


11. Goldberg P. USPSTF To Downgrade PSA Screening from "I" to "D" -- As In "Don't Do It". The Cancer Letter [Internet]. 2011; 37:[1-4 pp.]. Available from: http://www.cancerletter.com/articles/20111006.

Trends in prostate cancer incidence


Trends in prostate cancer incidence


Trends in prostate cancer incidence


Legend for Figure 1

Joinpoint analyses of prostate cancer age-specific incidence rates by stage at diagnosis, 1995-2012, plotted on a logarithmic scale.

Localized/Regional stage: ■ 50-69 years ● 70 + years

Distant stage: □ 50-69 years ○ 70 + years

Trend 1  --------

Trend 2  ------

Trend 3  ----- -

*APC is statistically different from zero at alpha = 0.05

APC = annual percent change (95% confidence intervals in parentheses)
Table 1. Trends in U.S. prostate cancer age-adjusted incidence rates (2000 U.S. standard population) by stage at diagnosis; ages 50 years and older, 1995-2012.

<table>
<thead>
<tr>
<th>Stage</th>
<th>Trend 1</th>
<th>Trend 2</th>
<th>Trend 3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Years</td>
<td>APC (95% CI)</td>
<td>Years</td>
</tr>
<tr>
<td>All</td>
<td>1995-2000</td>
<td>1.7 (-0.9, 4.3)</td>
<td>2000-2010</td>
</tr>
<tr>
<td>Localized/Regional</td>
<td>1995-2001</td>
<td>2.6 (0.4, 4.9)*</td>
<td>2001-2010</td>
</tr>
<tr>
<td>Distant</td>
<td>1995-1997</td>
<td>-8.4 (-14.1, -2.3)*</td>
<td>1997-2003</td>
</tr>
</tbody>
</table>

Abbreviations: APC = annual percent change, CI = confidence interval

*The APC is statistically different from zero at alpha = 0.05.
<table>
<thead>
<tr>
<th>Year at Diagnosis</th>
<th>APC</th>
</tr>
</thead>
<tbody>
<tr>
<td>1995-2000</td>
<td>1.7 (-1.3, 4.9)</td>
</tr>
<tr>
<td>1995-2001</td>
<td>-5.3 (-6.8, -3.8)*</td>
</tr>
<tr>
<td>1995-2004</td>
<td>-4.9 (-6.2, -3.6)*</td>
</tr>
<tr>
<td>2000-2007</td>
<td>-2.7 (-4.9, -0.5)*</td>
</tr>
<tr>
<td>2001-2012</td>
<td>-1.4 (-2.1, -0.7)*</td>
</tr>
<tr>
<td>2004-2012</td>
<td>1.7 (0.2, 3.2)*</td>
</tr>
<tr>
<td>2007-2012</td>
<td>-8.5 (-11.6, -5.2)*</td>
</tr>
<tr>
<td>2010-2012</td>
<td>-12.3 (-23.0, -0.1)*</td>
</tr>
</tbody>
</table>

*Significant trend
Trends in United States prostate cancer incidence rates by age and stage, 1995-2012

Richard M. Hoffman, Angela Meisner, Wadih Arap, et al.

Cancer Epidemiol Biomarkers Prev  Published OnlineFirst December 8, 2015.

Updated version  Access the most recent version of this article at: doi:10.1158/1055-9965.EPI-15-0723

Author Manuscript  Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.